Zhejiang Jiuzhou Pharmaceutical Co Ltd
SSE:603456
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Zhejiang Jiuzhou Pharmaceutical Co Ltd
Cash from Operating Activities
Zhejiang Jiuzhou Pharmaceutical Co Ltd
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Z
|
Zhejiang Jiuzhou Pharmaceutical Co Ltd
SSE:603456
|
Cash from Operating Activities
-¥149.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Cash from Operating Activities
¥4.8B
|
CAGR 3-Years
20%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Cash from Operating Activities
¥11.5B
|
CAGR 3-Years
105%
|
CAGR 5-Years
41%
|
CAGR 10-Years
17%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Cash from Operating Activities
¥4.6B
|
CAGR 3-Years
13%
|
CAGR 5-Years
4%
|
CAGR 10-Years
8%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Cash from Operating Activities
¥8.8B
|
CAGR 3-Years
26%
|
CAGR 5-Years
23%
|
CAGR 10-Years
25%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Cash from Operating Activities
¥4.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
171%
|
CAGR 10-Years
N/A
|
|
Zhejiang Jiuzhou Pharmaceutical Co Ltd
Glance View
Founded in 1973, Zhejiang Jiuzhou Pharmaceutical Co. Ltd. has steadily navigated the evolving tides of the global pharmaceutical industry with a compelling blend of innovation and traditional business acumen. Rooted in China's dynamic Zhejiang province, the company initially focused on manufacturing basic pharmaceutical intermediates. Over the years, it strategically expanded its operations, becoming a key player in both the Active Pharmaceutical Ingredients (APIs) and Contract Development and Manufacturing Organization (CDMO) sectors. This dual focus has allowed Jiuzhou Pharmaceutical to innovate and offer comprehensive services, ranging from drug development to commercial manufacturing, effectively appealing to a broad range of customers including some of the world's leading pharmaceutical companies. At the heart of Jiuzhou Pharmaceutical's success lies its commitment to research and development, a cornerstone that supports its diversification strategy. The company leverages its extensive expertise and cutting-edge technology to improve existing drugs while also participating in the development of new, patented pharmaceuticals. By fostering strong partnerships with global pharmaceutical giants, Jiuzhou effectively integrates itself into the larger pharmaceutical ecosystem, providing customized solutions that resonate with market demand. This business model not only reinforces its financial growth but also establishes Zhejiang Jiuzhou as an indispensable contributor to advancements in medicine, continually enhancing its reputation on the international stage.
See Also
What is Zhejiang Jiuzhou Pharmaceutical Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
-149.7m
CNY
Based on the financial report for Mar 31, 2026, Zhejiang Jiuzhou Pharmaceutical Co Ltd's Cash from Operating Activities amounts to -149.7m CNY.